IL5 and asthma: Several reports showed that blood eosinophil counts predict treatment outcomes with mepolizumab (IL-5 targeting therapy) use, especially in severe asthma, including the observation that with a baseline blood eosinophil count ≥0.15 × 109/L, clinically meaningful reductions in exacerbation rates are achieved.30